2. Academic Validation
  3. Discovery of a Selective DNMT1 Degrader with a Unique Molecular Glue Mechanism as a Potential Therapeutic Agent for Acute Myeloid Leukemia

Discovery of a Selective DNMT1 Degrader with a Unique Molecular Glue Mechanism as a Potential Therapeutic Agent for Acute Myeloid Leukemia

  • J Med Chem. 2026 Apr 9;69(7):7756-7781. doi: 10.1021/acs.jmedchem.5c02991.
Lan Ma 1,  Kun Zhang 1 2,  Yubo Wang 1,  Nan Zheng 1 3,  Xiaoting Gu 1,  Chao Li 4,  Weiya Li 4,  Ning Li 1,  Yulin Liu 1,  Zhongao Lu 1,  Jianping Lin 1 5,  Xin Wang 1,  Jing Xu 4,  Ziqi Huang 1,  Xingli Zhao 4,  Dongmei Li 1,  Shuangwei Liu 1,  Guang Yang 1
Affiliations

Affiliations

  • 1 The State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, Nankai University, Tianjin 300071, P. R. China.
  • 2 Institute of Chemistry, Henan Academy of Sciences, Zhengzhou 450002, P. R. China.
  • 3 Guangdong Institute for Drug Control, Guangzhou 510700, P. R. China.
  • 4 Department of Hematology, Department of Pharmacy, Oncology Center, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Tianjin 300071, P. R. China.
  • 5 Biodesign Center, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, Tianjin 300308, P. R. China.
PMID: 41873809 DOI: 10.1021/acs.jmedchem.5c02991
Abstract

Previous research indicated that DNA Methyltransferase 1 (DNMT1) inhibitors can induce UHRF1-mediated degradation of the DNMT1 protein. However, the underlying degradation mechanism remains poorly understood. During our investigation of a series of quinazoline-based DNMT1 inhibitors, we serendipitously discovered a highly potent and selective DNMT1 Degrader 6k. Employing techniques such as surface plasmon resonance (SPR) and molecular dynamics (MD) simulations, we have for the first time clearly demonstrated that 6k can promote a significant direct interaction between DNMT1 and UHRF1 proteins via a molecular glue mechanism under cell-free conditions. Further biological evaluations indicated that this DNMT1 Degrader exhibits potent inhibitory effects on AML cells both in vitro and in vivo. The results show that compound 6k effectively suppresses the proliferation of primary AML cells and significantly extends the survival of experimental Animals in the patient-derived xenograft (PDX) model. More importantly, 6k demonstrates favorable bioavailability and safety profiles, suggesting its promising potential for further development.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z